BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 30231396)

  • 1. Predicting and Preventing Anthracycline-Related Cardiotoxicity.
    Armenian S; Bhatia S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():3-12. PubMed ID: 30231396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study.
    Skitch A; Mital S; Mertens L; Liu P; Kantor P; Grosse-Wortmann L; Manlhiot C; Greenberg M; Nathan PC
    BMC Cancer; 2017 Aug; 17(1):519. PubMed ID: 28774277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced cardiomyopathy.
    Higgins AY; O'Halloran TD; Chang JD
    Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine.
    Armenian SH
    Ann Nutr Metab; 2016; 68 Suppl 3():10-14. PubMed ID: 27931027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac toxicity after anthracycline chemotherapy in childhood.
    Iarussi D; Indolfi P; Galderisi M; Bossone E
    Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
    Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
    JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors.
    Hildebrandt MAT; Reyes M; Wu X; Pu X; Thompson KA; Ma J; Landstrom AP; Morrison AC; Ater JL
    Sci Rep; 2017 Aug; 7(1):9698. PubMed ID: 28851949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
    Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M
    Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.
    Zerra P; Cochran TR; Franco VI; Lipshultz SE
    Expert Opin Pharmacother; 2013 Aug; 14(11):1497-513. PubMed ID: 23705955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline-Induced Cardiomyopathy in Adults.
    Tan TC; Neilan TG; Francis S; Plana JC; Scherrer-Crosbie M
    Compr Physiol; 2015 Jul; 5(3):1517-40. PubMed ID: 26140726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.
    Lipshultz SE; Diamond MB; Franco VI; Aggarwal S; Leger K; Santos MV; Sallan SE; Chow EJ
    Paediatr Drugs; 2014 Oct; 16(5):373-89. PubMed ID: 25134924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired exercise capacity and left ventricular function in long-term adult survivors of childhood acute lymphoblastic leukemia.
    Christiansen JR; Kanellopoulos A; Lund MB; Massey R; Dalen H; Kiserud CE; Ruud E; Aakhus S
    Pediatr Blood Cancer; 2015 Aug; 62(8):1437-43. PubMed ID: 25832752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthracycline-associated cardiotoxicity in survivors of childhood cancer.
    Trachtenberg BH; Landy DC; Franco VI; Henkel JM; Pearson EJ; Miller TL; Lipshultz SE
    Pediatr Cardiol; 2011 Mar; 32(3):342-53. PubMed ID: 21221562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
    Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
    Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.